KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherReceivables RefundsShares Repurchased
Ratios

Sarepta Therapeutics (SRPT) Receivables - Other (2016 - 2025)

Sarepta Therapeutics has reported Receivables - Other over the past 15 years, most recently at $104.1 million for Q4 2025.

  • Quarterly results put Receivables - Other at $104.1 million for Q4 2025, up 200.87% from a year ago — trailing twelve months through Dec 2025 was $104.1 million (up 200.87% YoY), and the annual figure for FY2025 was $104.1 million, up 200.87%.
  • Receivables - Other for Q4 2025 was $104.1 million at Sarepta Therapeutics, down from $128.7 million in the prior quarter.
  • Over the last five years, Receivables - Other for SRPT hit a ceiling of $128.7 million in Q3 2025 and a floor of $8000.0 in Q4 2021.
  • Median Receivables - Other over the past 5 years was $29.4 million (2021), compared with a mean of $40.0 million.
  • Biggest five-year swings in Receivables - Other: tumbled 99.98% in 2021 and later surged 41287.5% in 2022.
  • Sarepta Therapeutics' Receivables - Other stood at $8000.0 in 2021, then surged by 41287.5% to $3.3 million in 2022, then soared by 800.03% to $29.8 million in 2023, then increased by 16.11% to $34.6 million in 2024, then surged by 200.87% to $104.1 million in 2025.
  • The last three reported values for Receivables - Other were $104.1 million (Q4 2025), $128.7 million (Q3 2025), and $73.3 million (Q2 2025) per Business Quant data.